The result at week 68: Continued semaglutide 2.4 mg: lost an additional 7.9% of body weight (total loss from baseline: 17.4%) Switched to placebo: regained 6.9% of body weight (net loss from baseline: 5.0%) Thats a roughly 15-point difference in body weight between the two groups at the end of the trial, attributable entirely to whether the medication continued
Common sites may include the abdomen, outer thigh, or back of the upper arm when the medication instructions and healthcare provider permit
Vin ung trng da Glutathione cn ngn nga lo ha vt tri
Low blood sugar episodes, which are more likely if someone is taking insulin or sulfonylureas alongside Wegovy, can mimic flushing and sweating and require different management
We are closely watching how these treatments affect mental health
Your healthcare provider determines the appropriate maintenance dose based on your individual response, tolerability, and weight-loss goals